| Bioactivity | YKL-1-116 is a selective and covalent inhibitor of Cdk7. YKL-1-116 does not target Cdk9, Cdk12, or Cdk13. YKL-1-116 is more potent than THZ1 (HY-80013) toward both Cdk7WT and Cdk7as, although Cdk7as is relatively resistant to this compound as well[1]. |
| Name | YKL-1-116 |
| CAS | 1957202-71-9 |
| Formula | C34H38N8O3 |
| Molar Mass | 606.72 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kalan S, et al. Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors. Cell Rep. 2017 Oct 10;21(2):467-481. |
YKL-1-116
CAS: 1957202-71-9 F: C34H38N8O3 W: 606.72
YKL-1-116 is a selective and covalent inhibitor of Cdk7. YKL-1-116 does not target Cdk9, Cdk12, or Cdk13. YKL-1-116 is m
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.